Literature DB >> 18326968

Mechanisms and treatment of resistant hypertension.

Eduardo Pimenta1, Krishna K Gaddam, Suzanne Oparil.   

Abstract

Resistant hypertension is defined as blood pressure (BP) that remains uncontrolled in spite of the use of >/=3 antihypertensive medications. Stricter BP goals, higher obesity rates, older age, and increased use of exogenous BP-elevating substances are related to an increasing prevalence of resistant hypertension. The evaluation of patients with resistant hypertension is focused on identifying contributing and secondary causes of hypertension, including hyperaldosteronism, obstructive sleep apnea, chronic kidney disease, renal artery stenosis, and pheochromocytoma. Hyperaldosteronism is now recognized as the most common cause of resistant hypertension, and all patients with resistant hypertension should be screened with a plasma aldosterone/renin ratio even if the serum potassium level is normal. Treatment includes removal of contributing factors, appropriate management of secondary causes, and use of effective multidrug regimens. Recent studies indicate that the addition of spironolactone to standard treatment induces significant BP reduction in most patients with resistant hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18326968      PMCID: PMC8110156          DOI: 10.1111/j.1751-7176.2008.08143.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  15 in total

1.  Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension.

Authors:  Mari K Nishizaka; Monique Pratt-Ubunama; Mohammad A Zaman; Stacey Cofield; David A Calhoun
Journal:  Am J Hypertens       Date:  2005-06       Impact factor: 2.689

Review 2.  Cardiovascular effects of the cyclooxygenase inhibitors.

Authors:  William B White
Journal:  Hypertension       Date:  2007-01-29       Impact factor: 10.190

3.  Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals.

Authors:  Eni C Okonofua; Kit N Simpson; Ammar Jesri; Shakaib U Rehman; Valerie L Durkalski; Brent M Egan
Journal:  Hypertension       Date:  2006-01-23       Impact factor: 10.190

4.  Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial.

Authors:  Christianne L Roumie; Tom A Elasy; Robert Greevy; Marie R Griffin; Xulei Liu; William J Stone; Kenneth A Wallston; Robert S Dittus; Vincent Alvarez; Janice Cobb; Theodore Speroff
Journal:  Ann Intern Med       Date:  2006-08-01       Impact factor: 25.391

5.  High prevalence of unrecognized sleep apnoea in drug-resistant hypertension.

Authors:  A G Logan; S M Perlikowski; A Mente; A Tisler; R Tkacova; M Niroumand; R S Leung; T D Bradley
Journal:  J Hypertens       Date:  2001-12       Impact factor: 4.844

6.  The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

Authors:  James R Sowers; William B White; Bertram Pitt; Andrew Whelton; Lee S Simon; Nathaniel Winer; Alan Kivitz; Hein van Ingen; Thomas Brabant; John G Fort
Journal:  Arch Intern Med       Date:  2005-01-24

7.  Differential control of systolic and diastolic blood pressure : factors associated with lack of blood pressure control in the community.

Authors:  D M Lloyd-Jones; J C Evans; M G Larson; C J O'Donnell; E J Roccella; D Levy
Journal:  Hypertension       Date:  2000-10       Impact factor: 10.190

8.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

Review 9.  Hypertension in renal parenchymal disease: why is it so resistant to treatment?

Authors:  V M Campese; N Mitra; D Sandee
Journal:  Kidney Int       Date:  2006-03       Impact factor: 10.612

Review 10.  Primary aldosteronism: diagnosis and treatment.

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

View more
  16 in total

Review 1.  Resistant hypertension--its identification and epidemiology.

Authors:  Pantelis A Sarafidis; Panagiotis Georgianos; George L Bakris
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

2.  Cardiovascular Regulation in Obstructive Sleep Apnea.

Authors:  Michael G Ziegler; Milos Milic; Hamzeh Elayan
Journal:  Drug Discov Today Dis Models       Date:  2011

Review 3.  Hypertension: issues in control and resistance.

Authors:  Marion R Wofford; Deborah S Minor
Journal:  Curr Hypertens Rep       Date:  2009-10       Impact factor: 5.369

Review 4.  Management of hypertension in the elderly.

Authors:  Eduardo Pimenta; Suzanne Oparil
Journal:  Nat Rev Cardiol       Date:  2012-03-13       Impact factor: 32.419

5.  Prescribing patterns in the treatment of hypertension among underserved African American elderly.

Authors:  Hamed Yazdanshenas; Mohsen Bazargan; Gail Orum; Leila Loni; Navid Mahabadi; Baqar Husaini
Journal:  Ethn Dis       Date:  2014       Impact factor: 1.847

Review 6.  Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

Review 7.  Epidemiology of resistant hypertension.

Authors:  Pantelis A Sarafidis
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-03-28       Impact factor: 3.738

8.  Do Obese Individuals With Hypertension Have More Difficult-to-Control Blood Pressure and End Organ Damage Than Their Nonobese Counterparts?

Authors:  Mark David Jesky; Manvir Kaur Hayer; Mark Thomas; Indranil Dasgupta
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-03-23       Impact factor: 3.738

9.  Resistant hypertension workup and approach to treatment.

Authors:  Anastasios Makris; Maria Seferou; Dimitris P Papadopoulos
Journal:  Int J Hypertens       Date:  2010-12-26       Impact factor: 2.420

10.  Aldosterone excess or escape: Treating resistant hypertension.

Authors:  Samira Ubaid-Girioli; Leoní Adriana de Souza; Juan Carlos Yugar-Toledo; Luiz Cláudio Martins; Sílvia Ferreira-Melo; Otávio Rizzi Coelho; Cristina Sierra; Antonio Coca; Eduardo Pimenta; Heitor Moreno
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-05       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.